TESTOSTERONE ENANTHATE AT A DOSE OF 200 MG/WEEK DECREASES HDL-CHOLESTEROL LEVELS IN HEALTHY-MEN
TESTOSTERONE ENANTHATE AT A DOSE OF 200 MG/WEEK DECREASES HDL-CHOLESTEROL LEVELS IN HEALTHY-MEN
复制标题
DOI：
10.1111/ijan.1995.18.5.237
复制
发表时间：
1995-10-01
影响因子：
--
通讯作者：
BREMNER, WJ
中科院分区：
文献类型：
--
作者：
MERIGGIOLA, MC;MARCOVINA, S;BREMNER, WJ
世界卫生组织在一项多中心、多阶段的试验中检验了仅雄激素可提供有效男性避孕药的概念。该试验的结果表明，睾酮的食用者，睾酮酸（TE），以200毫克/周的剂量施用，具有非常高的避孕效果，并表明，至少在某些人群中，雄激素单独可能提供一个可行的选择来控制男性生育能力。睾酮是男性冠状动脉疾病（CAD）的性别相关危险因素之一。流行病学和介入性研究未能在睾酮和高密度脂蛋白胆固醇（HDL-C）之间建立令人信服的关系。因此，人们担心单雄激素男性避孕药可能对脂蛋白资产产生负面影响。在这项研究中，我们分析了正常健康男性长期（12个月）服用TE （200mg /周）的效果。从36名男性中抽取血液样本（6名男性>禁食10小时=第一组；30名男性>禁食4小时=第二组），在注射开始前每月抽取一次（对照组），在整个研究期间每3个月抽取一次（治疗组），并在停止TE注射后1个月抽取一次（恢复组）。在这些样本中测量总胆固醇（chol）、甘油三酯、HDL-C和LDL-C水平。同时监测生化参数。在两组（禁食和非禁食）的男性中，TE给药导致HDL-C水平显著下降（15-20%），且无论基础HDL-C水平如何都发生了相当程度的下降。对其他脂蛋白无统计学意义的影响。考虑到所有男性，在治疗的第3个月，78%的男性的HDL-C水平下降了，第6个月下降了83%，第9个月下降了94%，第12个月下降了97%。在所有男性中，HDL-C的下降在停止TE治疗1个月内是可逆的。结果表明：(1)注射200 mg TE/周可使正常男性HDL-C下降15-20%，对其他脂蛋白无影响；(2)在1年的注射期内TE的抑制作用保持不变，且TE给药时间与男性HDL-C水平下降的比例呈直接关系。(3)停止TE治疗后1个月内HDL-C降低是可逆的。这些数据对于设计进一步的男性避孕研究，以及解释睾酮水平、HDL-C水平和潜在心血管风险之间的关系具有重要意义。
The concept that androgen alone can provide an effective male contraceptive has been tested in a multicentre, multiphase trial by the World Health Organization. Results from this trial showed that an eater of testosterone, testosterone enanthate (TE), administered at a dose of 200 mg/week, has a very high contraceptive efficacy, and suggested that, at least in some populations, androgen alone might provide a viable option for the control of male fertility. It has been claimed that testosterone represents one of the gender-related risk factors for coronary artery disease (CAD) in men. Epidemiological and interventional studies have failed to establish a convincing relationship between testosterone and high density lipoprotein cholesterol (HDL-C). Therefore, there is concern about possible negative effects on lipoprotein asset of an androgen-alone male contraceptive. In this study we analysed the effects of long-term (12 months) administration of TE (200 mg/week) in normal healthy men. Blood samples (six men >10 h fast = Group 1; 30 men >4 h fast = Group 2) were drawn from 36 men, monthly before the beginning of the injections (control), every 3 months throughout the study period (treatment), and 1 month after stopping TE injections (recovery). Total cholesterol (chol), triglycerides, HDL-C and LDL-C levels were measured in these samples. Biochemical parameters were also monitored. TE administration induced a significant decrease (15-20%) in HDL-C levels that was of comparable magnitude in men from both groups (fasting and non-fasting) and occurred regardless of basal HDL-C levels. No statistically significant effect on other lipoproteins was detected. Considering all men together, HDL-C levels were decreased in 78% of the men by month 3, 83% by month 6, 94% by month 9 and 97% by month 12 of treatment. In all men the HDL-C decrease was reversible within 1 month of stopping TE administration. It is concluded that: (1) injection of 200 mg TE/week causes a 15-20% decrease in HDL-C in normal men with no effect on other lipoproteins, (2) the suppressive effect of TE is maintained throughout the 1-year-injection period, and a direct relationship between the duration of TE administration and the proportion of men showing decreased HDL-C levels, was observed. (3) The HDL-C decrease was reversible within 1 month of stopping TE administration. These data will be important in designing further studies on male contraception, and in interpreting the relationship between testosterone levels, HDL-C levels and potential cardiovascular risk.